(Reuters) - U.S. drugmaker Pfizer Inc <PPE.N> is considering options, including a sale of its women's health portfolio, Bloomberg reported on Thursday, citing sources familiar with the matter.
A sale of the division, which has annual sales of about $1.2 billion, could fetch about $2 billion and draw bids from both private equity firms and rival pharmaceutical companies, Bloomberg reported https://www.bloomberg.com/news/articles/2018-11-01/pfizer-said-to-weigh-sale-of-2-billion-women-s-health-portfolio.
Pfizer did not immediately respond to Reuters request for comment.
Allergan Plc <AGN.N> said in May it planned to sell off its women's health and infectious disease units, to focus on its core businesses.
(Reporting by Manogna Maddipatla in Bengaluru; Editing by Shailesh Kuber)